1. Home
  2. ACET vs BAFN Comparison

ACET vs BAFN Comparison

Compare ACET & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.54

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$7.90

Market Cap

40.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
BAFN
Founded
1947
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
93.5M
40.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACET
BAFN
Price
$0.54
$7.90
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
1.9M
5.6K
Earning Date
11-05-2025
01-29-2026
Dividend Yield
N/A
2.02%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$58,931,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$6.40
52 Week High
$1.12
$19.75

Technical Indicators

Market Signals
Indicator
ACET
BAFN
Relative Strength Index (RSI) 35.12 34.84
Support Level $0.50 $8.05
Resistance Level $0.57 $8.07
Average True Range (ATR) 0.05 0.08
MACD 0.00 0.04
Stochastic Oscillator 18.38 0.00

Price Performance

Historical Comparison
ACET
BAFN

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: